ACTRN12618001480279招募中2 期
Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria
- •1.Signed informed consent obtained prior to any study specific procedures and willingness to comply with study requirements
- •2.Age greater than or equal to 18 years
- •3.Histologically confirmed, metastatic colorectal adenocarcinoma treated with less than or equal to 2 cycles of doublet chemotherapy
- •4.ECOG performance status of 0-2
- •5.Life expectancy of greater than or equal to 3 months
- •6.Adequate major organ function to receive doublet chemotherapy as judged by the treating clinician
- •7.No contraindication to any of the 3 cytotoxic agents (5FU, oxaliplatin and irinotecan)
- •8.Recent imaging of chest, abdomen and pelvis. It is recommended that this should be within 4 weeks of first chemotherapy dose (no more than 8 weeks).
- •Please note: Every patient enrolled in the study is then entered in the TRACC Registry to enable the data collection for the study.
排除标准
- •Exclusion Criteria
- •1.Previous chemotherapy and/or biologic therapy for CRC, except for adjuvant treatment if completed more than 6 months earlier
- •2.Not suitable for doublet chemotherapy
- •3.Significant concomitant medical condition which the treating clinician believes precludes the patient from enrolling in the study
研究者
相似试验
进行中（未招募）
不适用
Phase II study of Oxaliplatin / Irinotecan / Cetuximab as first line therapy in locally advanced or metastatic gastric cancerPatients with histologically proven inoperable locally advanced or metastatic gastric cancerEUCTR2006-001989-16-ATAGMT
进行中（未招募）
1 期
Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patientsnresectable locally advanced or metastatic Gastric CancerMedDRA version: 20.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006128-79-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH40
进行中（未招募）
不适用
Treatment with Oxaliplatin and Irinotecan in colorectal metastatic tumors with high expression of thymidilate synthase (TS). - IRINOXPATIENTS WITH METASTATIC COLORECTAL CANCERMedDRA version: 9.1Level: LLTClassification code 10062099Term: Rectal neoplasmEUCTR2008-000217-30-ITAZIENDA OSPEDALIERA SENESE
已完成
1 期
PhaseI/II study of irinotecan and oxaliplatin combination chemotherapy in patients with gemcitabine and 5-fluorouracil refractory pancreatic cancer.pancreatic cancerJPRN-UMIN000015877Chiba cancer center30
进行中（未招募）
2 期
Phase2 trial of oxaliplatin, irinotecan and S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancerpancreatic cancerJPRN-jRCTs011190008Komatsu Yoshito40